CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $20,190,000 | -32.3% | 266,430 | 0.0% | 0.57% | -23.3% |
| Q3 2021 | $29,822,000 | -30.9% | 266,430 | 0.0% | 0.74% | -32.2% |
| Q2 2021 | $43,132,000 | +32.9% | 266,430 | 0.0% | 1.10% | +13.2% |
| Q1 2021 | $32,464,000 | -20.4% | 266,430 | 0.0% | 0.97% | -20.0% |
| Q4 2020 | $40,793,000 | +83.1% | 266,430 | 0.0% | 1.21% | +21.1% |
| Q3 2020 | $22,284,000 | +13.8% | 266,430 | 0.0% | 1.00% | -13.9% |
| Q2 2020 | $19,580,000 | +73.3% | 266,430 | 0.0% | 1.16% | -3.3% |
| Q1 2020 | $11,299,000 | +15.8% | 266,430 | +21.1% | 1.20% | +1.1% |
| Q3 2018 | $9,757,000 | -24.5% | 220,000 | 0.0% | 1.19% | -34.4% |
| Q2 2018 | $12,927,000 | +109.5% | 220,000 | +63.0% | 1.81% | +66.6% |
| Q1 2018 | $6,171,000 | – | 135,000 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |